title: [Pharmacological, pharmacokinetic, and clinical profile of palonosetron hydrochloride (ALOXI I.V. Injection 0.75 mg), a novel antiemetic 5-HT3-receptor antagonist].
authors: hiro-ajioka@taiho.co.jp
authors: Hirofusa
authors: H
authors: Ajioka
authors: Fumio
authors: F
authors: Morita
authors: Yushiro
authors: Y
authors: Akizawa
authors: Kenichiro
authors: K
authors: Yoshida
authors: Ryuichi
authors: R
authors: Kitamura
authors: Hisami
authors: H
authors: Takimoto
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002945:Cisplatin / Q000009:adverse effects; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D004347:Drug Interactions; D006801:Humans; D007275:Injections, Intravenous; D007546:Isoquinolines / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D000077924:Palonosetron; D011812:Quinuclidines / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D016032:Randomized Controlled Trials as Topic; D051381:Rats; D012702:Serotonin Antagonists / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D014839:Vomiting / Q000139:chemically induced* / Q000517:prevention & control*
chemical_list: D000970:Antineoplastic Agents; D007546:Isoquinolines; D011812:Quinuclidines; D012702:Serotonin Antagonists; D000077924:Palonosetron; D002945:Cisplatin